REGN
Q3 2026 EPS Estimate
$10.85
Jul 30, 2026 · Reports before open
Revenue Estimate
$3.82B
FY2026E EPS$46.46
FY2027E EPS$54.15

Analyst Sentiment

Wall St. Consensus
Buy
23 analysts·High coverage
68
Score
17 Buy (74%)6 Hold (26%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1774%
Hold
626%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$641.00
+1.3%
Consensus
$857.50
+35.5%
Bull
$995.00
+57.2%
12-Month Target Range23 analysts
$641.00$857.50$995.00
Current $632.90Consensus
Current Price
$632.90
Upside to Consensus
$224.60

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+10.61%
EPS+16.56%
FY2028
Rev+7.44%
EPS+12.41%
FY2029
Rev+10.80%
EPS+18.40%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$15.92B$17.61B$18.92B$20.97B$21.46B
Low$15.24B$16.10B$18.91B$19.47B$19.93B
High$16.68B$19.21B$18.93B$22.59B$23.13B
EBITDA Avg$6.92B$7.65B$8.22B$9.11B$9.32B
Low$6.62B$6.99B$8.21B$8.46B$8.65B
High$7.25B$8.34B$8.22B$9.81B$10.04B
EBIT Avg$6.44B$7.12B$7.65B$8.48B$8.68B
Low$6.16B$6.51B$7.65B$7.87B$8.06B
High$6.75B$7.77B$7.65B$9.14B$9.35B
Net Income Avg$4.97B$5.13B$5.79B$7.83B$7.76B
Low$4.51B$3.27B$5.40B$7.10B$7.04B
High$5.43B$7.16B$8.05B$8.62B$8.54B
EPS Avg$46.46$54.15$60.88$72.07$71.47
Low$41.54$30.14$49.75$65.38$64.83
High$49.99$65.95$74.09$79.35$78.68
Analysts (Rev / EPS)20 / 1620 / 922 / 815 / 611 / 6
Quarterly
MetricQ2 2026Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$3.82B$4.20B$4.35B$3.93B$4.29B$4.52B$5.05B
Low$3.65B$3.82B$3.95B$3.57B$3.90B$4.11B$4.58B
High$4.18B$4.52B$4.79B$4.34B$4.73B$4.99B$5.57B
EBITDA Avg$1.66B$1.82B$1.89B$1.71B$1.86B$1.96B$2.19B
Low$1.59B$1.66B$1.71B$1.55B$1.69B$1.78B$1.99B
High$1.82B$1.96B$2.08B$1.88B$2.06B$2.17B$2.42B
EBIT Avg$1.54B$1.70B$1.76B$1.59B$1.74B$1.83B$2.04B
Low$1.48B$1.55B$1.60B$1.44B$1.58B$1.66B$1.85B
High$1.69B$1.83B$1.94B$1.75B$1.91B$2.02B$2.25B
Net Income Avg$1.17B$1.41B$1.41B$1.24B$1.43B$1.55B$1.86B
Low$911M$1.05B$1.24B$1.09B$1.26B$1.37B$1.64B
High$1.46B$1.62B$1.59B$1.40B$1.62B$1.76B$2.11B
EPS Avg$10.85$13.08$13.06$11.50$13.26$14.41$17.26
Low$8.46$9.75$11.50$10.12$11.67$12.68$15.19
High$13.55$15.07$14.81$13.04$15.03$16.33$19.56
Analysts (Rev / EPS)13 / 1513 / 156 / 106 / 66 / 66 / 66 / 6

Earnings Surprises

Recent Analyst Actions

May 19, 2026Canaccord Genuity
Regeneron price target lowered to $875 from $1,057 at Canaccord
Target:$875.00
+39.0%from $629.68
May 18, 2026Wolfe Research
Regeneron price target lowered to $860 from $900 at Wolfe Research
Target:$860.00
+36.6%from $629.36
May 18, 2026Evercore ISI
Regeneron price target lowered to $825 from $875 at Evercore ISI
Target:$825.00
+33.1%from $619.84
May 18, 2026RBC Capital
Regeneron price target lowered to $707 from $762 at RBC Capital
Target:$707.00
+14.1%from $619.62
May 18, 2026Truist Financial
Regeneron price target lowered to $778 from $796 at Truist
Target:$778.00
+25.5%from $619.95
May 18, 2026BMO Capital
Regeneron price target lowered to $730 from $900 at BMO Capital
Target:$730.00
+4.5%from $698.25
May 18, 2026Piper Sandler
Regeneron price target lowered to $855 from $875 at Piper Sandler
Target:$855.00
+22.4%from $698.25
May 18, 2026Leerink Partners
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
Target:$641.00
-8.2%from $698.25
May 1, 2026Guggenheim
Regeneron price target raised to $995 from $975 at Guggenheim
Target:$995.00
+40.7%from $707.06
Apr 30, 2026Morgan Stanley
Regeneron price target lowered to $788 from $796 at Morgan Stanley
Target:$788.00
+12.1%from $703.18
Apr 30, 2026Truist Financial
Regeneron price target lowered to $796 from $801 at Truist
Target:$796.00
+14.9%from $692.75
Apr 30, 2026Barclays
Regeneron price target lowered to $917 from $923 at Barclays
Target:$917.00
+33.6%from $686.36
Apr 22, 2026Raymond James
Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)
Target:$910.00
+21.9%from $746.58
Apr 10, 2026Morgan Stanley
Regeneron price target raised to $796 from $769 at Morgan Stanley
Target:$796.00
+6.7%from $746.15
Apr 8, 2026Bernstein
Regeneron price target lowered to $921 from $925 at Bernstein
Target:$921.00
+18.8%from $775.53
Mar 9, 2026Truist Financial
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results
Target:$818.00
+6.2%from $770.32
Mar 6, 2026Barclays
Barclays Starts Regeneron Pharma (REGN) at Overweight
Target:$923.00
+20.7%from $764.93
Mar 2, 2026RBC Capital
Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital
Target:$765.00
-2.4%from $784.06
Feb 9, 2026Guggenheim
Regeneron price target raised to $975 from $865 at Guggenheim
Target:$975.00
+24.1%from $785.51
Feb 2, 2026Cantor Fitzgerald
Regeneron price target raised to $800 from $740 at Cantor Fitzgerald
Target:$800.00
+5.6%from $757.59
Feb 2, 2026Robert W. Baird
Regeneron price target raised to $742 from $630 at Baird
Target:$742.00
-1.8%from $755.34
Feb 2, 2026Oppenheimer
Regeneron price target raised to $865 from $750 at Oppenheimer
Target:$865.00
+16.7%from $741.45
Feb 2, 2026Tudor Pickering
Regeneron Pharma (REGN) PT Raised to $925 at Bernstein SocGen Group
Target:$925.00
+22.8%from $753.13
Feb 1, 2026Morgan Stanley
Regeneron price target raised to $769 from $768 at Morgan Stanley
Target:$769.00
+3.7%from $741.45
Jan 30, 2026Raymond James
Regeneron price target raised to $870 from $820 at Raymond James
Target:$870.00
+17.3%from $741.45
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.